Atara Biotherapeutics (NASDAQ:ATRA) Posts Quarterly Earnings Results, Beats Estimates By $0.84 EPS

Atara Biotherapeutics (NASDAQ:ATRA) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84, Zacks reports. The business had revenue of $40.19 million during the quarter, compared to the consensus estimate of $23.00 million. During the same quarter last year, the business earned ($16.50) EPS.

Atara Biotherapeutics Stock Down 10.4 %

ATRA traded down $1.49 during trading on Thursday, reaching $12.77. 124,721 shares of the stock traded hands, compared to its average volume of 107,307. The stock’s 50-day moving average is $8.95 and its 200 day moving average is $10.32. Atara Biotherapeutics has a 12 month low of $6.50 and a 12 month high of $39.50. The stock has a market capitalization of $62.70 million, a PE ratio of -0.50 and a beta of 0.50.

Analyst Ratings Changes

ATRA has been the subject of several analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their price target for the company from $25.00 to $18.00 in a research report on Friday, August 16th. Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, The Goldman Sachs Group cut their price objective on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research note on Wednesday, July 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Atara Biotherapeutics has an average rating of “Hold” and a consensus target price of $16.67.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.